Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Institut Jules Bordet, Brussels

Universitair Ziekenhuis Brussel, Brussels

GZA Ziekenhuizen - Campus Sint-Augustinus, Wilrijk

UZ Antwerpen, Antwerp

GHdC Notre Dame, Charleroi

Centre Hospitalier de l'Ardenne, Libramont

Herbert Irving Comprehensive Cancer Center, New York

Weill Cornell Medical College New York Presbyterian Hospital, New York

Eastchester Center for Cancer Care / BRANY, The Bronx

Centre Francois Baclesse, Caen

Holy Cross Hospital, Silver Spring

Virginia Oncology Associates - Hampton, Chesapeake

Oncology and Hematology Assoc. of SW VA, Inc., Salem

West Virginia University, Morgantown

Mount Sinai Medical Center, Miami Beach

Florida Cancer Research Institute, Plantation

Erlanger Medical Center, Chattanooga

University Hospitals of Cleveland, Cleveland

Centre Catherine de Sienne, Nantes

Henry Ford Medical Center, Novi

University of Minnesota, Minneapolis

Mayo Clinic, Rochester

University of Kansas Medical Center Research Institute, Inc., Westwood

Clinique Victor Hugo - Centre Jean Bernard, Le Mans

Texas Health Physicians Group, Plano

Texas Oncology, P.A., Dallas

Texas Oncology, P.A. - Tyler, Tyler

The University of Texas MD Anderson Cancer Center, Houston

Millennium Oncology, Houston

Cancer Care Network of South Texas - SAT&BC, San Antonio

University of Colorado Cancer Center, Aurora

Rocky Mountain Cancer Centers, LLP, Lakewood

Institut Sainte Catherine, Avignon

Los Angeles Hematology, Los Angeles

Santa Barbara Hematology Oncology Medical Group, Inc., Santa Barbara

University of California at San Francisco (PARENT), San Francisco

Roswell Park Cancer Institute, Buffalo

University of Cincinnati Physicians Company, LLC, Cincinnati

Texas Oncology, P.A. - Beaumont, Beaumont

UT Southwestern Medical Center, Dallas